^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TmGPC2 01 CAR-T

    i
    Other names: TmGPC2 01 CAR-T, GPC2 CAR-T
    Associations

    News

    Trials
    Company:
    Gilead, The Children’s Hospital of Philadelphia, University of Pennsylvania
    Drug class:
    GPC-2-targeted CAR-T immunotherapy
    Associations

    News

    Trials
    5ms
    D3-GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma and small cell lung cancer. (PubMed, Clin Cancer Res)
    These data validate GPC2 as a bona fide CAR T cell target in neuroblastoma and other cancers. The safety and preliminary efficacy of GPC2 CAR T cells are being tested in a first-in-human phase 1 clinical trial for children with relapsed/refractory neuroblastoma (NCT05650749).
    Preclinical • Journal
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    TmGPC2 01 CAR-T
    almost3years
    GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Stephan Grupp MD PhD | Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> May 2023
    Enrollment open • Trial initiation date • CAR T-Cell Therapy
    |
    TmGPC2 01 CAR-T